Robert Lorne Hopfner

Insider Reports History

Location
C/O Bay City Capital, Llc, 750 Battery Street, Suite 400, San Francisco, CA
Signature
/s/ Gregory S. Moss, Attorney-in-Fact
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by Robert Lorne Hopfner:

Stock Role Class Num Shares Value Price $ Report Date Ownership
Rallybio Corp Director Option (Right to Buy) 28.5K $51.5K $0.70 May 13, 2025 Direct
Rallybio Corp Director Option (Right to Buy) 16.5K $29.2K $1.77 May 15, 2024 Direct
Inozyme Pharma, Inc. Director Common Stock 0 $0 $4.00 Jul 1, 2025 By Pivotal
Evommune, Inc. Director, 10%+ Owner Common Stock 1.63M Nov 7, 2025 By Pivotal bioVenture Partners Fund I, L.P.
Evommune, Inc. Director, 10%+ Owner Common Stock 1.44M Nov 7, 2025 By NFLS Delta III Limited
Evommune, Inc. Director, 10%+ Owner Common Stock 295K Nov 7, 2025 By Pivotal bioVenture Partners Fund II, L.P.
Vaxcyte, Inc. Director Stock Option (right to buy) 15K Jun 2, 2021 Direct
Evommune, Inc. Director, 10%+ Owner Common Stock 3.03K Nov 7, 2025 By Trust
Evommune, Inc. Director, 10%+ Owner Series A Preferred Stock 0 Nov 7, 2025 By NFLS Delta III Limited
Evommune, Inc. Director, 10%+ Owner Series A Preferred Stock 0 Nov 7, 2025 By Pivotal bioVenture Partners Fund I, L.P.
Evommune, Inc. Director, 10%+ Owner Series B Preferred Stock 0 Nov 7, 2025 By NFLS Delta III Limited
Evommune, Inc. Director, 10%+ Owner Series B Preferred Stock 0 Nov 7, 2025 By Pivotal bioVenture Partners Fund I, L.P.
Evommune, Inc. Director, 10%+ Owner Series C Preferred Stock 0 Nov 7, 2025 By NFLS Delta III Limited
Evommune, Inc. Director, 10%+ Owner Series C Preferred Stock 0 Nov 7, 2025 By Pivotal bioVenture Partners Fund II, L.P.
Evommune, Inc. Director, 10%+ Owner Series C Preferred Stock 0 Nov 7, 2025 By Pivotal bioVenture Partners Fund I, L.P.
Evommune, Inc. Director, 10%+ Owner Series Seed Preferred Stock 0 Nov 7, 2025 By NFLS Delta III Limited
Evommune, Inc. Director, 10%+ Owner Series Seed Preferred Stock 0 Nov 7, 2025 By Pivotal bioVenture Partners Fund I, L.P.
Evommune, Inc. Director, 10%+ Owner Series Seed Preferred Stock 0 Nov 7, 2025 By Trust

Insider Reports Filed by Robert Lorne Hopfner

Symbol Company Period Transactions Value $ Form Type Date Filed Role
EVMN Evommune, Inc. Nov 7, 2025 14 $0 4 Nov 12, 2025 Director, 10%+ Owner
EVMN Evommune, Inc. Nov 5, 2025 0 $0 3 Nov 5, 2025 Director, 10%+ Owner
INZY Inozyme Pharma, Inc. Jul 1, 2025 2 -$18M 4 Jul 3, 2025 Director
RLYB Rallybio Corp May 13, 2025 1 $0 4 May 15, 2025 Director
RLYB Rallybio Corp Jan 2, 2025 1 $51.5K 4 Jan 6, 2025 Director
INZY Inozyme Pharma, Inc. Jun 18, 2024 1 $0 4 Jun 20, 2024 Director
RLYB Rallybio Corp May 15, 2024 1 $0 4 May 17, 2024 Director
INZY Inozyme Pharma, Inc. Aug 1, 2023 2 $4M 4 Aug 3, 2023 Director
INZY Inozyme Pharma, Inc. Jun 13, 2023 1 $0 4 Jun 15, 2023 Director
RLYB Rallybio Corp May 17, 2023 1 $0 4 May 19, 2023 Director
INZY Inozyme Pharma, Inc. May 11, 2023 2 $2.85M 4 May 15, 2023 Director
INZY Inozyme Pharma, Inc. Mar 29, 2023 1 $1.56M 4 Mar 30, 2023 Director
INZY Inozyme Pharma, Inc. Mar 27, 2023 2 $841K 4 Mar 29, 2023 Director
INZY Inozyme Pharma, Inc. Jun 10, 2022 1 $0 4 Jun 14, 2022 Director
RLYB Rallybio Corp May 24, 2022 1 $0 4 May 26, 2022 Director
INZY Inozyme Pharma, Inc. Apr 19, 2022 1 $3.95M 4 Apr 20, 2022 Director
RLYB Rallybio Corp Jan 3, 2022 1 $0 4 Jan 5, 2022 Director
RLYB Rallybio Corp Jul 29, 2021 0 $0 3 Jul 29, 2021 Director
RLYB Rallybio Corp Jul 28, 2021 4 $7.5M 4 Aug 4, 2021 Director
INZY Inozyme Pharma, Inc. Jun 23, 2021 1 $0 4 Jun 24, 2021 Director
PCVX Vaxcyte, Inc. Jun 2, 2021 1 $0 4 Jun 3, 2021 Director